Human immunodeficiency virus and hepatitis C co-infection in sub-Saharan West Africa

British Journal of Biomedical Science

Volumn 63, Issue 1, 2006, Pages 29-37

  Mboto, C I ^a   Davies, A ^b   Fielder, M ^b   Jewell, A P ^b  

^a Royal Victoria Teaching Hospital Gambia   (Gambia)

^b KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

Co infection; Hepatitis C; HIV

Indexed keywords

AFRICA; CIRCUMCISION; DEVELOPED COUNTRY; DISEASE TRANSMISSION; ENDEMIC DISEASE; EPIDEMIC; EXPOSURE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; POVERTY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33645772238     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2006.11732716     Document Type: Review

References (93)

1. Auvert B, Buve A, Ferry B et al. Study Group on the Heterogeneity of HIV Epidemics in African Cities. Ecological and individual level analysis of risk factors for HIV infection in four urban populations in sub Saharan Africa with different levels of HIV infection. AIDS 2001; 15: S15-S30.
2. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
3. Dodig M, Tavill AS. Hepatitis C and human immunodeficiency virus coinfections. J Clin Gastroenterol 2001; 33(5): 367-74.
4. World Health Organization. Global prevalence of hepatitis C virus. Wkly Epidemiol Rec 1997; 46: 343.
5. Combe P, La Ruche G, Bonard D et al. DYSCER-CI Study Group. Hepatitis B and C infections, human immunodeficiency virus and other sexually transmitted infections among women of childbearing age in Cote d'Ivoire, West Africa. Trans R Soc Trop Med Hyg 2001; 95 (5): 493-6.
6. Zylberberg H, Pialoux G, Carnot F, Landau A, Brechot C, Pol S. Rapidly evolving hepatitis C virus related cirrhosis in a human immunodeficiency virus infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998; 27: 12558.
7. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998; 12: 1167.
8. Dieterich DT, Purow JM, Rajapaksa R. Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV Semin Liver Dis 1999; 19: 8794.
9. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 7480.
10. UNAIDS/WHO. AIDS Epidemic Update. 2003.
11. Quintana M, del Amo J, Barrasa A et al. Progression of HIV infection and mortality by hepatitis C infection in patients with haemophilia over 20 years. Haemophilia 2003; 9 (5): 605-12.
12. Njouom R, Pasquier C, Ayouba A et al. High rate of hepatitis C virus infection and predominance of genotype 4 among elderly inhabitants of a remote village of the rain forest of South Cameroon. J Med Virol 2003; 71 (2): 219-25.
13. Hodges M, Sanders E, Aitken C. Seroprevalence of hepatitis markers; HAV, HBV, HCV and HEV amongst primary school children in Freetown, Sierra Leone. West Afr J Med 1998; 17 (1): 36-7.
14. Filippini P, Coppola N, Scolastico C et al. Does HIV infection favor the sexual transmission of hepatitis C? Sex Trans Dis 2001; 28 (12): 725-9.
15. World Health Organization. Hepatitis C: global prevalence (update). Wkly Epidemiol Rec 1999; 74: 4218.
16. Awoyemi OB, Ige OM, Onadeko BO. Prevalence of active pulmonary tuberculosis in human immunodeficiency virus seropositive adult patients in University College Hospital, Ibadan, Nigeria. Afr J Med Med Sci 2002; 31 (4): 329-32.
17. Bailey AC. Aggressive Kaposi sarcoma in Zambia, 1983. Lancet 1984; i: 1318-20.
18. De Cock KM. Epidemiology and the emergence of human immunodeficiency virus and acquired immune deficiency syndrome. Philos Trans R Soc Lond B Sci 2001; 356 (1410): 795-8.
19. Ng H. AIDS in Africa: a regional overview. Harv AIDS Rev 2000: 2-5.
20. Van Der Sande MA, Schim Van Der Loeff MF, Bennett RC et al. Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS 2004; 18 (14): 1933-41.
21. De Cock KM, Brun Vezinet F. Epidemiology of HIV-2 infection. AIDS 1989; 3 (Suppl 1): S89-95.
22. Hughes A, Corrah T. Human immunodeficiency virus type 2 (HIV2). Blood Rev 1990; 4 (3): 158-64.
23. Schim van der Loeff MF, Sarge-Njie R, Ceesay S et al. Regional differences in HIV trends in The Gambia: results from sentinel surveillance among pregnant women. AIDS 2003; 17 (12): 1841-6.
24. Monteiro-Grillo M, Sousa AP, Galvao J, Yueh M, Neves C, Ribeiro-da-Silva J. Clinical correlations in HIV-1 and HIV-2 infected patients. Eur J Ophthalmol 1993; 3 (1): 13-20.
25. Bertherat E, Georges-Courbot MC, Nabias R, Georges AJ, Renaut A. Seroprevalence of four sexually transmitted diseases in a semi-urban population of Gabon. Int J STD AIDS 1998; 9 (1): 31-6.
26. Peeters M, Koumare B, Mulanga C, Brengues C et al. Genetic subtypes of HIV type 1 and HIV type 2 strains in commercial sex workers from Bamako, Mali. AIDS Res Hum Retroviruses 1998; 14 (1): 51-8
27. Marlink R, Kanki P, Thior I et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265 (5178): 1587-90.
28. N'Gbichi JM, De Cock KM, Batter V et al. HIV status of female sex partners of men reactive to HIV-1, HIV-2 or both viruses in Abidjan, Cote d'Ivoire. AIDS 1995; 9 (8): 951-4.
29. Wainberg. HIV-1 subtype distribution and the problem of drug resistance. AIDS 2004; 18 (Suppl 3): S63-8.
30. Renjufi B, Gilbert P, Chaplin B et al. Tanzanian Vitamin and HIV Study Group. Preferential in utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS. 2004; 18 (12): 1629-36.
31. Kingsley LA, Detels R, Kaslow R et al. Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet 1987; i: 345-9.
32. Shattock RJ, Moore JE Inhibiting sexual transmission of HIV-1 infection Nature Reviews: Microbiology 2003; 1: 26-34.
33. Hardy DB. Cultural practices contributing to the transmission of human immunodeficiency virus in Africa. Rev Infect Dis 1987; 9 (6): 1109-19.
34. Zein NN. The epidemiology and natural history of hepatitis C virus infection. Cleve Clin J Med 2003; 70 (Suppl 4): S2-6.
35. Luksamijarulkul P, Thammata N, Sujirarat D, Tiloklurs M. Hepatitis C virus infection among Thai blood donors: antibody prevalence, risk factors and development of risk screening form. Southeast Asian J Trop Med Public Health 2004; 35 (1): 147-54.
36. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 82532.
37. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24 (Suppl 2): 3-8.
38. McHutchison JG. Understanding hepatitis C. Am J Manag Care 2004; 10 (2 Suppl): S21-9.
39. Hassan MM, Zaghloul AS, El-Serag HB et al. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol 2001; 33 (2): 123-6.
40. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2002; 2 (5): 293-302.
41. Gretch D. Diagnostic tests for hepatitis C. Hepatology 1997; 26: 43S-47S.
42. Stauber R. Epidemiology and transmission of hepatitis C. Wien Med Wochenschr 2000; 150 (23-24): 460-2.
43. Vardas E, Sitas F, Seidel K, Casteling A, Sim J Prevalence of hepatitis C virus antibodies and genotypes in asymptomatic, first-time blood donors in Namibia. Bull World Health Organ 1999; 77 (12): 965-72.
44. Ahmed SD, Cuevas LE, Brabin BJ et al. Seroprevalence of hepatitis B and C and HIV in Malawian pregnant women. J Infect 1998; 37 (3): 248-51.
45. Mets T, Smitz J, Ngendahayo P, Sabbe L, Bigilimana I, Ngirabatware B. Hepatitis C virus infection in African patients with liver cirrhosis or primary hepatocellular carcinoma. Scand J Gastroenterol 1993; 28 (4): 331-4.
46. Debonne JM, Nicand E, Boutin JP, Carre D, Buisson Y. Hepatitis C in tropical areas Med Trop (Mars) 1999; 59 (4 Pt 2): 508-16.
47. Gisselquist D, Perrin L, Minkin SF. Parallel and overlapping HIV and blood borne hepatitis epidemics in Africa. Int J STD AIDS 2004; 15 (3): 145-52.
48. Garcia-Samaniego J, Soriano V, Castilla J et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. Am J Gastroenterol 1997; 92: 11304.
49. Kirk GD, Lesi OA, Mendy M et al. The Gambia Liver Cancer Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 2004; 39 (1): 211-9.
50. Jeannel D, Fretz C, Traore Y et al. Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. J Med Virol 1998; 55: 92-7.
51. Mwangi JW. Viral markers in a blood donor population. East Afr Med J 1999; 76 (1): 35-7.
52. Halim NK, Ajayi OI. Risk factors and seroprevalence of hepatitis C antibody in blood donors in Nigeria. East Afr Med J 2000; 77 (8): 410-2.
53. Ampofo W, Nii-Trebi N, Ansah J et al. Prevalence of blood-borne infectious diseases in blood donors in Ghana. J Clin Microbiol 2002; 40 (9): 3523-5.
54. Bozdayi AM, Asian N, Bozdayi G et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol 2004; 149 (11): 2115-29.
55. Ndjomou J, Kupfer B, Kochan B, Zekeng L, Kaptue L, Matz B. Hepatitis C virus infection and genotypes among human immunodeficiency virus high-risk groups in Cameroon. J Med Virol 2002; 66 (2): 179-86.
56. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997; 26: 48590.
57. Monga HK, Rodriguez-Barradas MC, Breaux K et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240-7.
58. Kiyosawa K, Sodeyama T, Tanaka E et al. Hepatitis C in hospital employees with needle stick injuries. Ann Intern Med 1991; 115: 3679.
59. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbidity and Mortality Weekly Report 1998; 47 (RR-19): 1-39.
60. Centers for Disease Control and Prevention. HIV/AIDS surveillance report. Atlanta, GA: CDC, 1999.
61. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients coinfected with human immunodeficiency virus: a cross-sectional analysis of the U.S. Adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-7.
62. Ayele W, Nokes DJ, Abebe A et al. Higher prevalence of anti-HCV antibodies among HIV-positive compared to HIV-negative inhabitants of Addis Ababa, Ethiopia. J Med Virol 2002; 68 (1): 12-7.
63. Menendez C, Sanchez-Tapias JM, Kahigwa E et al. Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. J Med Virol 1999; 58 (3): 215-20.
64. Fan WM, Zhu WF, Zhang SY et al. Nine-year follow-up of hepatitis C virus infection in a rural area of Hebei province, China. Zhonghua Yi Xue Za Zhi 2004; 84 (5): 392-6.
65. Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol 1998; 148 (1): 88-96.
66. Harder J, Walter E, Riecken B, Ihling C, Bauer TM. Hepatitis C virus infection in intravenous drug users. Clin Microbiol Infect 2004; 10 (8): 768-70.
67. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6: 60210.
68. Goldmann DA. Blood-borne pathogens and nosocomial infections. J Allergy Clin Immunol 2002; 110 (2 Suppl): S21-6.
69. Donahue JG, Nelson KE, Muñoz A et al. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol 1991; 134: 1206-11.
70. Thomas DL, Zenilman JM, Alter HJ et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore: an analysis of 309 sex partnerships. J Infect Dis 1995; 171: 76875.
71. Fretz C, Jeannel D, Stuyver L et al. HCV infection in a rural population of the Central African Republic (CAR): evidence for three additional subtypes of genotype 4. J Med Virol 1995; 47 (4): 435-7.
72. Harlow LL, Rose JS, Morokoff PJ et al. Women HIV sexual risk takers: related behaviors, interpersonal issues, and attitudes. Womens Health 1998; 4 (4): 407-39.
73. Clumeck N, Vandeperr P, Carael M, Rouvroy D, Nzaramba D. Heterosexual promiscuity among African patients with AIDS (Letter). N Engl J Med 1985; 313: 182.
74. Yerly S, Quadri R, Negro F et al Nosocomial outbreak of multiple blood borne viral infections. J Infect Dis 2001; 184 (3): 369-72.
75. Rockstroh, JK, Spengler U. HIV and hepatitis C virus co-infection. Lancet Infect Dis 2004; 4: 437-44.
76. Virelink H, van der Poel CL, Reesink HW et al. Look back study of infectivity of anti-HCV ELISA positive blood components. Lancet 1995; 345: 95-6.
77. Centers for Disease Control and Prevention. Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy. MMWR Morb Mortal Wkly Rep 1998; 47 (RR-17): 1-14.
78. Patrick DM, Buxton JA, Bigham M, Mathias RG. Public health and hepatitis C. Canadian I Public Health 2000; 91: S18-S21.
79. Gray RH, Wawer MJ, Brookmeyer R et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357: 1149-53.
80. Bloom DE, Glied S. Benefits and costs of HIV testing. Science 1991; 252 (5014): 1798-804.
81. Cohen D. The economic impact of the HIV epidemic. Issues Paper No 2. UNDP 1992.
82. WHO/AFRO. Ensuring blood transfusion safety in Africa. 27 August 2001-1 September 2001. Press Release.
83. Chiwuzie J, Ukoli F, Okojie O, Isah E, Eriator E. Traditional practitioners are here to stay. World Health Forum 1987; 8: 240-244.
84. Green E, Zokwe B, Dupree J. The experience of an AIDS prevention programme focused on South African traditional healers. Soc Sci Med 1995; 40: 503.
85. Gillett J, Pawluch D, Cain R. How people with HIV/AIDS manage and assess their use of complementary therapies: a qualitative analysis. J Assoc Nurses AIDS Care 2002; 13 (2): 17-27.
86. Okonofua FE, Ogonor JI, Omorodion FI, Coplan FM, Kaufman JA, Heggenhougen K. Assessment of services for the prevention and treatment of sexually transmitted diseases among adolescents in Nigeria. Sex Trans Dis 1999; 26 (1): 184-90.
87. Bishaw M. Promoting traditional medicine in Ethiopia: a brief historical review of government policy. Soc Sci Med 1991; 33 (2): 193-200.
88. Oppong AC. Healers in transition. Soc Sci Med 1989; 28 (6): 605-12.
89. Fassin D, Fassin E. Traditional medicine and the stakes of legitimation in Senegal. Soc Sci Med 1988; 27 (4): 353-7.
90. Wake DJ, Cutting WA. Blood transfusion in developing countries: problems, priorities and practicalities. Trop Doct 1998; 28 (1): 4-8.
91. Owusu-Ofori S, Temple J, Sarkodie F, Anokwa M, Candotti D, Allain JP. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion. 2005; 45 (2): 133-40.
92. Sherman GG, Matsebula TC, Jones SA. Is early HIV testing of infants in poorly resourced prevention of mother to child transmission programmes unaffordable? Trop Med M Health 2005; 10 (11): 1108-13.
93. Rouet F, Ekouevi DK, Chaix ML et al. Transfer and evaluation of an automated, low-cost real-time reverse franscription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 2005; 43 (6): 2709-17.